LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 4 of total 4

Search options

  1. Article ; Online: Glomerular Filtration Rate in Asphyxiated Neonates Under Therapeutic Whole-Body Hypothermia, Quantified by Mannitol Clearance.

    Deferm, Neel / Annink, Kim V / Faelens, Ruben / Schroth, Michael / Maiwald, Christian A / Bakkali, Loubna El / van Bel, Frank / Benders, Manon J N L / van Weissenbruch, Mirjam M / Hagen, Anja / Smits, Anne / Annaert, Pieter / Franz, Axel R / Allegaert, Karel

    Clinical pharmacokinetics

    2021  Volume 60, Issue 7, Page(s) 897–906

    Abstract: Background: Therapeutic hypothermia (TH) is an established intervention to improve the outcome of neonates with moderate-to-severe hypoxic-ischemic encephalopathy resulting from perinatal asphyxia. Despite this beneficial effect, TH may further affect ... ...

    Abstract Background: Therapeutic hypothermia (TH) is an established intervention to improve the outcome of neonates with moderate-to-severe hypoxic-ischemic encephalopathy resulting from perinatal asphyxia. Despite this beneficial effect, TH may further affect drug elimination pathways such as the glomerular filtration rate.
    Objectives: The objective of this study was to quantify the effect of TH in addition to asphyxia on mannitol clearance as a surrogate for the glomerular filtration rate.
    Methods: The effect of asphyxia and TH (mild vs moderate/severe) on mannitol clearance was assessed using a population approach, based on mannitol observations collected in the ALBINO (ALlopurinol in addition to TH for hypoxic-ischemic Brain Injury on Neurocognitive Outcome) trial, as some were exposed to a second dose of 10 mg/kg intravenous mannitol as placebo to ensure blinding. Pharmacokinetic analysis and model development were conducted using NONMEM version 7.4.
    Results: Based on 77 observations from 17 neonates (TH = 13), a one-compartment model with first-order linear elimination best described the observed data. To account for prenatal glomerular filtration rate maturation, both birthweight and gestational age were implemented as clearance covariates using an earlier published three-quarters power function and a sigmoid hyperbolic function. Our final model predicted a mannitol clearance of 0.15 L/h for a typical asphyxia neonate (39.5 weeks, birthweight 3.25 kg, no TH), lower than the reported value of 0.33 L/h for a healthy neonate of similar age and weight. By introducing TH as a binary covariate on clearance, the additional impact of TH on mannitol clearance was quantified (60% decrease).
    Conclusions: Mannitol clearance was decreased by approximately 60% in neonates undergoing TH, although this is likely confounded with asphyxia severity.
    Trial registration: ClinicalTrials.gov identifier NCT03162653.
    MeSH term(s) Asphyxia Neonatorum/therapy ; Female ; Glomerular Filtration Rate ; Humans ; Hypothermia ; Hypothermia, Induced ; Hypoxia-Ischemia, Brain/therapy ; Infant, Newborn ; Mannitol ; Pregnancy
    Chemical Substances Mannitol (3OWL53L36A)
    Language English
    Publishing date 2021-02-21
    Publishing country Switzerland
    Document type Journal Article ; Randomized Controlled Trial ; Research Support, Non-U.S. Gov't
    ZDB-ID 197627-8
    ISSN 1179-1926 ; 0312-5963
    ISSN (online) 1179-1926
    ISSN 0312-5963
    DOI 10.1007/s40262-021-00991-6
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Pharmacokinetic/Pharmacodynamic Modelling of Allopurinol, its Active Metabolite Oxypurinol, and Biomarkers Hypoxanthine, Xanthine and Uric Acid in Hypoxic-Ischemic Encephalopathy Neonates.

    Chu, Wan-Yu / Annink, Kim V / Nijstad, A Laura / Maiwald, Christian A / Schroth, Michael / Bakkali, Loubna El / van Bel, Frank / Benders, Manon J N L / van Weissenbruch, Mirjam M / Hagen, Anja / Franz, Axel R / Dorlo, Thomas P C / Allegaert, Karel / Huitema, Alwin D R

    Clinical pharmacokinetics

    2021  Volume 61, Issue 2, Page(s) 321–333

    Abstract: Background: Allopurinol, an xanthine oxidase (XO) inhibitor, is a promising intervention that may provide neuroprotection for neonates with hypoxic-ischemic encephalopathy (HIE). Currently, a double-blind, placebo-controlled study (ALBINO, NCT03162653) ... ...

    Abstract Background: Allopurinol, an xanthine oxidase (XO) inhibitor, is a promising intervention that may provide neuroprotection for neonates with hypoxic-ischemic encephalopathy (HIE). Currently, a double-blind, placebo-controlled study (ALBINO, NCT03162653) is investigating the neuroprotective effect of allopurinol in HIE neonates.
    Objective: The aim of the current study was to establish the pharmacokinetics (PK) of allopurinol and oxypurinol, and the pharmacodynamics (PD) of both compounds on hypoxanthine, xanthine, and uric acid in HIE neonates. The dosage used and the effect of allopurinol in this population, either or not undergoing therapeutic hypothermia (TH), were evaluated.
    Methods: Forty-six neonates from the ALBINO study and two historical clinical studies were included. All doses were administered on the first day of life. In the ALBINO study (n = 20), neonates received a first dose of allopurinol 20 mg/kg, and, in the case of TH (n = 13), a second dose of allopurinol 10 mg/kg. In the historical cohorts (n = 26), neonates (all without TH) received two doses of allopurinol 20 mg/kg in total. Allopurinol and oxypurinol population PK, and their effects on inhibiting conversions of hypoxanthine and xanthine to uric acid, were assessed using nonlinear mixed-effects modelling.
    Results: Allopurinol and oxypurinol PK were described by two sequential one-compartment models with an autoinhibition effect on allopurinol metabolism by oxypurinol. For allopurinol, clearance (CL) was 0.83 L/h (95% confidence interval [CI] 0.62-1.09) and volume of distribution (V
    Conclusion: The PK and PD of allopurinol, oxypurinol, hypoxanthine, xanthine, and uric acid in neonates with HIE were described. The dosing regimen applied in the ALBINO trial leads to the targeted XO inhibition in neonates treated with or without TH.
    MeSH term(s) Allopurinol/pharmacology ; Allopurinol/therapeutic use ; Biomarkers ; Enzyme Inhibitors ; Humans ; Hypoxanthine ; Hypoxia-Ischemia, Brain/drug therapy ; Infant, Newborn ; Oxypurinol/pharmacokinetics ; Uric Acid ; Xanthine ; Xanthine Oxidase
    Chemical Substances Biomarkers ; Enzyme Inhibitors ; Xanthine (1AVZ07U9S7) ; Uric Acid (268B43MJ25) ; Hypoxanthine (2TN51YD919) ; Allopurinol (63CZ7GJN5I) ; Xanthine Oxidase (EC 1.17.3.2) ; Oxypurinol (G97OZE5068)
    Language English
    Publishing date 2021-10-07
    Publishing country Switzerland
    Document type Journal Article ; Randomized Controlled Trial ; Research Support, Non-U.S. Gov't
    ZDB-ID 197627-8
    ISSN 1179-1926 ; 0312-5963
    ISSN (online) 1179-1926
    ISSN 0312-5963
    DOI 10.1007/s40262-021-01068-0
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Plasma hemopexin as a potential regulator of vascular responsiveness to angiotensin II.

    Bakker, Winston W / Spaans, Floor / el Bakkali, Loubna / Borghuis, Theo / van Goor, Harry / van Dijk, Evert / Buijnink, Joshua / Faas, Marijke M

    Reproductive sciences (Thousand Oaks, Calif.)

    2013  Volume 20, Issue 3, Page(s) 234–237

    Abstract: This brief review focuses on the functional activities of plasma hemopexin recently recognized by several authors. In particular, the protease-like activity of hemopexin in vitro is linked with downregulation of the vascular angiotensin II receptor in ... ...

    Abstract This brief review focuses on the functional activities of plasma hemopexin recently recognized by several authors. In particular, the protease-like activity of hemopexin in vitro is linked with downregulation of the vascular angiotensin II receptor in vivo, leading to vascular expansion. Also a potential mechanism of inhibition of hemopexin activity by extracellular adenosine triphosphate is considered.
    MeSH term(s) Angiotensin II/blood ; Animals ; Female ; Hemopexin/physiology ; Humans ; Male ; Pregnancy ; Protein Binding/physiology ; Vasoconstriction/physiology ; Vasodilation/physiology
    Chemical Substances Angiotensin II (11128-99-7) ; Hemopexin (9013-71-2)
    Language English
    Publishing date 2013-03
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't ; Review
    ZDB-ID 2276411-2
    ISSN 1933-7205 ; 1933-7191
    ISSN (online) 1933-7205
    ISSN 1933-7191
    DOI 10.1177/1933719112446081
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Nephrotic syndrome in The Netherlands: a population-based cohort study and a review of the literature.

    El Bakkali, Loubna / Rodrigues Pereira, Robert / Kuik, Dirk J / Ket, Johannes C F / van Wijk, Joanna A E

    Pediatric nephrology (Berlin, Germany)

    2011  Volume 26, Issue 8, Page(s) 1241–1246

    Abstract: Nephrotic syndrome (NS) is a clinical diagnosis with proteinuria, hypoalbuminaemia and oedema. NS is rare in children, and its incidence in The Netherlands is unknown. The aim of this study was to estimate the incidence of idiopathic NS in the ... ...

    Abstract Nephrotic syndrome (NS) is a clinical diagnosis with proteinuria, hypoalbuminaemia and oedema. NS is rare in children, and its incidence in The Netherlands is unknown. The aim of this study was to estimate the incidence of idiopathic NS in the Netherlands. All paediatric patients (age 0-18 years) with a newly diagnosed NS in the Netherlands were registered by the Dutch Pediatric Surveillance Unit during the years 2003 until 2006, secondary NS was excluded. All paediatricians filled out questionnaires about the first clinical findings of the patients and incidences were calculated. A literature review on incidences of childhood NS was conducted. The incidence of NS in children in the Netherlands in the years 2003 until 2006 was 1.52/ 100, 000 children/ year. The median age at diagnosis was 3.88 years with a mean age of 5.08 years. A significant male:female ratio of 2.04:1 was found. This prospective study of NS in the Netherlands revealed an incidence of 1.52:100, 000 children/year, and is similar to the incidences found all over the world.
    MeSH term(s) Adolescent ; Age of Onset ; Child ; Child, Preschool ; Cohort Studies ; Female ; Humans ; Incidence ; Infant ; Infant, Newborn ; Male ; Nephrotic Syndrome/epidemiology ; Netherlands/epidemiology
    Keywords covid19
    Language English
    Publishing date 2011-05-01
    Publishing country Germany
    Document type Journal Article ; Research Support, Non-U.S. Gov't ; Review
    ZDB-ID 631932-4
    ISSN 1432-198X ; 0931-041X
    ISSN (online) 1432-198X
    ISSN 0931-041X
    DOI 10.1007/s00467-011-1851-8
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top